Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Cardinal Health, Inc.

The Immortal Humira? In Huge Test For US Biosimilar Policy, Brand May Still Have Edge

First Humira biosimilar launches raise worries about holes in US health system that may let the brand product continue to dominate. If Humira biosimilars can’t get a strong foothold, reform to biosimilar policy for medicines reimbursed through the pharmacy benefit may be necessary if the US wants to rely on these products to bring down the cost of brand biologics.

Biosimilars Biologics

Medtech 100: Big Three Companies Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Medtech 100 Commercial

Big Three Lead From The Front With Medtech Back On Solid Growth Footing

Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.

Outlook 2023 Sales & Earnings

Finance Watch: $1.32bn In New Biopharma VC Financings As Year-End Approaches

Private Company Edition: In recent weeks, 19 companies disclosed venture capital funding of $20m or more, including FogPharma with a $178m series D round and Apogee’s $169m launch. Also, Avalon BioVentures spun out of Avalon Ventures with a $135m fund.

Financing Innovation
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Distributors
  • Medical Devices
  • Services
  • Services
    • Home Infusion
    • Hospitals, Nursing Homes, Institutions
    • Pharmacy Services, PBMs
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • AccessClosure
    • Allegiance Healthcare Corporation
    • Cordis Corporation
    • Innovative Therapies, naviHealth
    • OutcomesMTM
    • The Harvard Drug Group
    • VIASYS Healthcare
UsernamePublicRestriction

Register